• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nascent Biotech Inc (OP:NBIO)

0.0008 UNCHANGED
Streaming Delayed Price Updated: 12:15 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0008
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0008
Today's Range 0.0008 - 0.0008
52wk Range 0.0001 - 0.0926
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Nascent Biotech Receives Delinquency Notification Related to its Delayed September 30, 2024 Financial Filing
January 21, 2025
From Nascent Biotech Inc
Via GlobeNewswire
News headline image
Nascent Biotech Presents at the July Emerging Growth Conference
July 30, 2024
Via ACCESSWIRE

Performance

YTD
N/A
N/A
1 Month
+166.7%
+166.7%
3 Month
-87.3%
-87.3%
6 Month
-38.5%
-38.5%
1 Year
-98.7%
-98.7%

More News

Read More
News headline image
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
April 16, 2024
Via ACCESSWIRE
News headline image
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
March 19, 2024
Via ACCESSWIRE
News headline image
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
January 09, 2024
Via ACCESSWIRE
News headline image
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
February 06, 2024
Via ACCESSWIRE
News headline image
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
December 19, 2023
Via ACCESSWIRE
News headline image
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
November 29, 2023
Via ACCESSWIRE
News headline image
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
August 22, 2023
Via ACCESSWIRE
News headline image
Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
June 07, 2023
Via ACCESSWIRE
News headline image
Nascent Biotech Regains Worldwide Rights for Pritumumab
May 26, 2023
Via ACCESSWIRE
News headline image
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
May 09, 2023
Via ACCESSWIRE
News headline image
Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
April 18, 2023
Via ACCESSWIRE
News headline image
Nascent Announces the Completion of Its Phase1 Clinical Trials
February 28, 2023
Via ACCESSWIRE
News headline image
Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
January 25, 2023
Via ACCESSWIRE
News headline image
Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial
January 10, 2023
Via ACCESSWIRE
News headline image
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
December 20, 2022
Via ACCESSWIRE
News headline image
Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
November 01, 2022
Via ACCESSWIRE
News headline image
Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research
October 04, 2022
Via ACCESSWIRE
News headline image
Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
September 13, 2022
Via ACCESSWIRE
News headline image
Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
July 19, 2022
Via ACCESSWIRE
News headline image
Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
July 19, 2022
From Nascent Biotech Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
June 07, 2022
From Nascent Biotech Inc.
Via AccessWire
News headline image
Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
May 04, 2022
From Nascent Biotech Inc.
Via AccessWire
News headline image
Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody
April 12, 2022
From Nascent Biotech Inc.
Via AccessWire

Frequently Asked Questions

Is Nascent Biotech Inc publicly traded?
Yes, Nascent Biotech Inc is publicly traded.
What exchange does Nascent Biotech Inc trade on?
Nascent Biotech Inc trades on the OTC Traded
What is the ticker symbol for Nascent Biotech Inc?
The ticker symbol for Nascent Biotech Inc is NBIO on the OTC Traded
What is the current price of Nascent Biotech Inc?
The current price of Nascent Biotech Inc is 0.0008
When was Nascent Biotech Inc last traded?
The last trade of Nascent Biotech Inc was at 01/06/26 12:15 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap